Saquinavir. Clinical pharmacology and efficacy

Clinical Pharmacokinetics

Volumn 34, Issue 3, 1998, Pages 189-201

  Vella, Stefano ^a   Floridia, Marco ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASTEMIZOLE; CD4 ANTIGEN; CISAPRIDE; CYTOCHROME P450; KETOCONAZOLE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TERFENADINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INTESTINE; LIVER METABOLISM; META ANALYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SURVIVAL; VIRUS INFECTION; VIRUS PARTICLE;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; SAQUINAVIR; VIRUS REPLICATION;

EID: 0031914073     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834030-00002     Document Type: Review

References (56)

1. Kohl NE, Emini EA, Schleif WA, et al. Active Human Immunodeficiency Virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4686-90
2. Kramer RA, Schaber MD, Skalka AM, et al. HTLV-III gag protein is processed in yeast cells by the virus pol protease. Science 1986; 231: 1580-4
3. Redshaw S. Inhibitors of HIV proteinase. Expert Opin Invest Drugs 1994; 3: 273-86
4. Pettit SC, Michael SF, Swanstrom R. The specificity of HIV protease. Perspect Drug Discov Des 1993; 1: 69-73
5. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 248: 858-61
6. Nagy K, Young M, Baboonian C, et al. Antiviral activity of Human Immunodeficiency virus type 1 in a single cycle of infection: evidence for a role of protease in the early phase. J Virol 1994; 68: 757-65
7. Bugelski PJ, Kirsh R, Hart TK. HIV protease inhibitors: effects on viral maturation and physiologic function in macrophages. J Leukoc Biol 1994; 56: 374-380
8. Noble S, Faulds D. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996; 52: 93-112
9. Craig JC, Greif C, Mills JS, et al. Anti-HIV activity of a specific inhibitor of HIV proteinase Ro31-8959 on virus maturation in a chronically infected promonocytic cell line. Antivir Chem Chemother 1991; 2: 188-96
10. Perno C-F, Aquaro S, Rosenwirth B, et al. In vitro activity of inhibitors of late stages of the replication og HIV in chronically infected macrophages. J Leukoc Biol 1994; 56: 381-6
11. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993; 37: 1207-3
12. Merrill DP, Manion DJ, Chou T-C, et al. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro. J Inf Dis 1997; 176: 265-8
13. Hoffmann-La Roche. Ro 31-8959 Saquinavir Invirase™, Investigational Drug Brochure, 1996 (data on file)
14. Williams PEO, Sampson AP, Green CP, et al. Disposition and bioavailability of the HIV proteinase inhibitor, Ro 31-8959. after single doses in healthy volunteers. Br J Clin Pharmacol 1992 Aug; 34: 155P-6P
15. Muirhead GJ, Shaw T, Williams PEO, et al. Pharmacokinetics of the HIV proteinase inhibitor, Ro 31-8959, after single and multiple oral doses in healthy volunteers. Br J Clin Pharmacol 1992 Aug; 34: 170P-1P
16. Shaw TM, Muirhead TJ, Parish N, et al. Tolerability and pharmacokinetics of single oral doses of Ro 1-8959, an HIV proteinase inhibitor. Br J Clin Pharmacol 1992 Aug; 34: 166P-7P
17. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Drug Metab Dispos 1997; 25 (2): 256-66
18. Merry C, Barry GM, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11: F29-F33
19. Schapiro JM, Winters MA, Stewart F, et al. The effect of high dose saquinavir on viral load and CD4+ cell counts in HIV-infected patients. Ann Intern Med 1996; 124: 1039-50
20. Vella S, Lazzarin A, Carosi G, et al. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antiviral Ther 1996; 1: 129-40
21. Kravcik S, Sahai J, Kerr B, et al. Nelfinavir mesylate increases saquinavir-soft gel capsule exposure in HIV+ patients [abstract 371]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
22. Rutschmann OT, Kaiser L, Perrin L, et al. Adding saquinavir to stavudine in patients with advanced HIV infection. AIDS 197; 11: 548
23. Conway B, on behalf of the NV 15355 study team. The activity and safety of two formulations of saquinavir combined with two nucleosides in treatment-naive patients [abstract 923]. 6th European Conference on Clinical Aspects and Treatment of HIV Infection; 1997 Oct 11-15; Hamburg
24. Sahai J. Risks and synergies from drug interactions. AIDS 1996; 10 Suppl. 1: S21-5
25. Merry C, Mulcahy F, Barry M, et al. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease. AIDS 1997; 11 (2): 268-9
26. Cox SR, Ferry JJ, Batts DH, et al. Delavirdine and marketed protease inhibitors: pharmacokinetic interaction studies in healthy volunteers [abstract 372]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington
27. Sahai J, Cameron W, Salgo M, et al. Drug interecation study between saquinavir and nevirapine [abstract 614]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington
28. Fiske WD, Mayers D, Wagner K, et al. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals [abstract 568]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington
29. Cox SR, Batts DH, Stewart F, et al. Evaluation of the pharmacokinetic interaction between saquinavir and delavirdine in healthy volunteers [abstract 372]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington
30. Norbeck D, Kumar G, Marsh K, et al. Ritonavir and saquinavir: potential for tw-dimensional synergy between HIV protease inhibitors [abstract LB-7]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco
31. Mccrea J, Buss N, Stone J, et al. Indinavir-saquinavir single dose pharmacokinetic study [abstract 608]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
32. Hirschel BJ, Rutschmann O, Fathi M, et al. Treatment of advanced HIV infection with ritonavir plus saquinavir [abstract]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
33. Barbour II, Clayton O. Efficacy and safety of quadruple combination therapy in treatment experienced HIV/AIDS patients [abstract 245]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington
34. Berger DS, Bucher G, Delaney K, et al. Further reduction in plasma HIV load in patients with advanced AIDS when a second protease inhibitor was added to a triple drug combination therapy [abstract]. 4th Conference on Retroviruses and Opportunistic Infectios; 1997 Jan 22-26; Washington
35. Angel JB, Parato K, Kumar A, et al. Rapid improvement in cell mediated immune function with initiation of ritonavir plus saquinavir in HIV immune deficiency [abstract 33]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington
36. Cameron W, Sun E, Markowitz M, Farthing C, et al. Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and acivity data [abstract Mo.B. 411] XIth International Conference on AIDS; 1996 Jul 7-12; Vancouver
37. Hirschel B, Lorenzi P, Yerly S, et al. Escape of viremia and rapid development of protease mutations in advanced HIV infection treated with saquinavir plus ritonavir [abstract 594]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington
38. Paulous S, Clavel F. Sequential selection by protease inhibitors: effects of ritonavir resistance on further selection for HIV resistance by saquinavir [abstract 598]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
39. Lee CA, Liang B-H, Wu EY, et al. Prediction of nelfinavir mesylate (Viracept) clinical drug interactons based on in vitro human P450 metabolism studies [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
40. Vella S. Clinical implications of resistance to antiretroviral drugs. AIDS Clin Care 1997; 9 (6): 47-52
41. Boucher C. Rational approaches to resistance: using saquinavir AIDS 1996; 10 Suppl. 1: S15-9
42. Roberts NA. Drug resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 1995, 9 Suppl. 2: S27-32
43. Condra JH, Schlief WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors [letter]. Nature 1995; 374: 569-71
44. Jacobsen H, Hanggi M, Ott M, et al. In vivo resistance to a Human Immunodeficiency Virus type I proteinase inhibitor: mutations, kinetics, and frequencies. J. Infect Dis 1996; 173: 1379-87
45. Vella S, Galluzzo C, Giannini G, et al. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res 1996; 29: 91-3
46. Valette M, Gerard Y, Ajana F, et al. Kaplan-Meier analysis of interruption probability of protease inhibitor, saquinavir, indinavir or ritonavir in 177 patients receiving a combination of protease inhibitors and reverse transcriptase inhibitors [abstract 197]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
47. Hoffmann-La Roche. Ro-31.8959. Saquinavir invirase™ Investigational Drug Brochure, W-144'962. 1996 (Data on file)
48. Collier A, Coombs RW, Schoenfeld DA, et al. Treatment of Human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996; 334: 1011-7
49. Lalezari J, Haubrich R, Burger HU, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir plus zalcitabine [abstract LB.B. 6033]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
50. Stellbrink HJ, for the INvirase International Phase III Trial (SV14604) Group. Clinical and survival benefits of saquinavir (SQV) in combination with zalcitabine (ddC) and zidovudine (ZDV) in untreated/minimally treated HIV-infected patients [abstract no. 923]. 6th European Conference on Clinical Aspects and Treatment of HIV Infection. 1997 Oct 11-15; Hamburg
51. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345: 952-5
52. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommndations of the International AIDS Society - USA Panel. JAMA 1997; 277: 1962-9
53. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morbid Mortal Wkly Rep 1996 Oct 25; 45: 921-5
54. Horsburgh CR. Advances in the prevention and treatment of Mycobacterium avium disease. N Engl J Med 1996; 335: 428-30
55. Angel JB, Parato K, Kumar A, et al. Rapid and sustained improvement in immune function during potent anti-HIV therapy with ritonavir plus saquinavir [abstract 1-75]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
56. Montaner, JSG, Rhone S, Yip, B, et al. The antiviral effect of ritonavir and saquinavir in combination among HIV-infected adults: results from a community-based study [abstract 437]. 6th European Conference on Clinical Aspects and Treatment of HIV Infection; 1997 Oct 11-15; Hamburg